North American Scientific will showcase its ClearPath, a high-dose rate radiation treatment created for breast brachytherapy, aiming to enhance current accelerated partial breast irradiation (APBI) treatment options. The company’s multichannel catheter system, which is inserted through a single incision, is designed to allow for low-dose or high-dose therapy. ClearPath reportedly offers physicians greater flexibility in treatment planning and dose optimization to the target region, while minimizing exposure to nearby healthy tissue.
If you enjoy this content, please share it with a colleague
Related Content
March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...
March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...
In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...
March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...
Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...
March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...
February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...
February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...
February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...
February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...